Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:43:41.354Z.
Calculation as of: 2026-10-06T20:43:41.354Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 08a81e5feebad721ee05cca7d6a51b618a8c436619bf2c78a545ff1cd4f886dd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$15.68M
PS Ratio
45.44
TTM Avg
60.86
3Y Avg
60.86
5Y Avg
60.86
Market Cap
$14.94M
PS Ratio
N/A
TTM Avg
1527.75
3Y Avg
1527.75
5Y Avg
1527.75
Market Cap
$16.52M
PS Ratio
4.76
TTM Avg
10.56
3Y Avg
13.22
5Y Avg
19.14
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jin Medical International Ltd. (ZJYL) | $15.58M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | 45.44 | 60.86 | 60.86 | 60.86 |
| BioCardia, Inc. (BCDA)vs › | $15.78M | N/A | 523.14 | 210.38 | 308.30 |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | 46.38 | 57.02 | 57.02 | 86.46 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A | 1527.75 | 1527.75 | 1527.75 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | 0.10 | 0.76 | 0.68 | 1.36 |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | 4.76 | 10.56 | 13.22 | 19.14 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | 0.55 | 0.37 | 0.68 | 11.87 |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | 111.45 | 20.09 | 7.30 | 5.50 |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | 1.27 | 1.77 | 177.00 | 2050.99 |
Half-year reporter: no trailing two-half-year basis, because the half-year figures cannot be checked against the annual report: the newest completed fiscal year's annual revenue and net income are both below 25 million, too small to compare.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
